JGC
SUPN icon

J. Goldman & Co’s Supernus Pharmaceuticals SUPN Stock Holding History

J. Goldman & Co’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-27,000
Closed -$921K – 584
2024
Q1 		$921K Buy
+27,000
New +$804K 0.03% 275

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

J. Goldman & Co's SUPN Position: Q4 2017 in Review

J. Goldman & Co sold out of Supernus Pharmaceuticals (SUPN) in Q4 2017, closing a stake of 77,147 shares — an estimated $3.09M sold.

J. Goldman & Co first reported a position in SUPN in Q1 2014 and held it in 3 quarters. The position peaked at $3.2M in Q1 2017. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

  • J. Goldman & Co reported no remaining Supernus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • J. Goldman & Co sold 77,147 Supernus Pharmaceuticals shares in Q4 2017, an estimated $3.09M.
  • J. Goldman & Co first reported a position in Supernus Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • J. Goldman & Co's Supernus Pharmaceuticals position peaked at $3.2M in Q1 2017.
  • 297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on J. Goldman & Co's 13F filing for Q4 2017, filed 14 Feb 2018.